Affymetrix Introduces New Axiom® 384HT Genotyping Format Enabling New Level of Cost-Effective, High-Throughput Genotyping St...
July 29 2013 - 6:30AM
Business Wire
Affymetrix, Inc. (NASDAQ: AFFX) announces the introduction of
the Axiom® 384HT genotyping format, a breakthrough cost-effective,
high-throughput format for genotyping in which 384 samples are
simultaneously processed with 384 discrete microarrays in a
microplate format analyzing up to 50,000 SNPs per sample.
The array content of the new Axiom 384HT format is fully
customizable, supporting applications ranging from detailed
assessment of human disease to high-throughput agricultural
screening and marker-assisted breeding. This new 384-array format
runs seamlessly on the existing GeneTitan® Multichannel Instrument,
providing researchers with a flexible choice of array formats on a
single automated platform for highly cost-effective identification,
validation, and screening of complex genetic traits.
“This latest addition to the Axiom genotyping platform uniquely
addresses a trend in both the human and agrigenomics fields of
study using population-optimized or application-focused content in
conjunction with low operating cost,” said Andy Last, Executive
Vice President of Genetic Analysis and Clinical Applications
Business Unit at Affymetrix. “The new format increases throughput
per system by fourfold, meeting the expanding demands of targeted
genotyping on very large numbers of samples at a significantly
reduced cost. Custom arrays can be manufactured and delivered to
customers in as little as four to six weeks.”
Limagrain, a French agricultural cooperative and the fourth
largest seed company in the world, has adopted the Axiom 384HT
format for routine genotyping of a number of plants using the Axiom
myDesign™ multi-species custom arrays in the 384-layout.
“We are very excited to adopt the Axiom 384HT format in our
routine genotyping program. This will give us the capacity to run
systematic marker-assisted selection with very large sets of
markers to improve the yield and quality of all our crops, which
will result in a strong acceleration of the various breeding
programs at Limagrain,” said Dr. Jean-Pierre Martinant, Deputy Head
of Research Support Functions for Limagrain Europe. “The Limagrain
production facilities are the first in the world to achieve the
capability to screen thousands of SNPs across many thousands of
plant samples in a rapid, affordable, and routine manner with the
384-array format.”
The new Axiom 384HT format addresses a current market need by
providing scientists with a very economical method of quickly
genotyping samples across up to 50,000 markers. Scientists can
transfer content from Axiom 96-layout arrays used in sequencing
validation and GWAS studies to Axiom 384-layout arrays with 100%
fidelity and functionality. The high-throughput assay combined with
the Axiom software for automated genotype calling in diploid and
complex polyploid species offers an elegant and superior platform
for routine genotyping applications.
As scientists make progress in decoding the genomes of various
human disease states, they can advance their research and
commercial objectives by translating those discoveries into
applications for routine human disease screening using custom
arrays in the 384-layout.
Researchers designing custom genotyping arrays receive design
support and expertise from Affymetrix’ team of bioinformatics
scientists to ensure streamlined SNP selection and intelligently
designed arrays that fulfill the specific objectives of their
study. The Axiom genotyping platform is the only platform that
offers the capability to genotype 384 samples across 50,000 markers
simultaneously and affordably genotype large sample collections
quickly.
To learn more about Axiom® Genotyping Solutions, please visit
http://www.affymetrix.com/axiom for applications in human diseases
research and www.affymetrix.com/agrigenotyping for applications in
agrigenomics.
PLEASE NOTE: Affymetrix®, the Affymetrix logo, Axiom®,
GeneTitan® and all other trademarks are the property of Affymetrix,
Inc. All other trademarks are the property of their respective
owners.
Products mentioned in this release are for research use only.
Not for diagnostic procedures.
SOURCE: Affymetrix, Inc.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2012, and other SEC reports for subsequent
quarterly periods.
About Affymetrix
Affymetrix technologies enable multiplex and simultaneous
analysis of biological systems at the cell, protein, and gene
level, facilitating the rapid translation of bench-top research
into clinical and routine use for human health and wellness.
We strive to provide leadership and support, partnering with our
customers in pharmaceutical, diagnostic, and biotechnology
companies, as well as leading academic, government, and non-profit
research institutes in their quest for answers toward using biology
for a better world.
More than 2,300 microarray systems have been shipped around the
world and more than 48,000 peer-reviewed papers have been published
citing our technologies. Affymetrix is headquartered in Santa
Clara, California, and has manufacturing facilities in Cleveland,
Ohio, San Diego, Vienna and Singapore. The Company has about 1,100
employees worldwide and maintains sales and distribution operations
across Europe, Asia, and Latin America. For more information about
Affymetrix, please visit www.affymetrix.com.
Affymetrix, Inc.Media
Contact:Mindy Lee-Olsen, 408-731-5523Vice President, Marketing
Servicesmindy_lee-olsen@affymetrix.comorInvestor
Contact:Doug Farrell, 408-731-5285Vice President, Investor
Relationsdoug_farrell@affymetrix.com
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2023 to Sep 2024